This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hill, R. P. Articles by Stanley, J. A. Search for Related Content PubMed PubMed Citation Articles by Hill, R. P. Articles by Stanley, J. A.

The Response of Hypoxic B16 Melanoma Cells to in Vivo Treatment with Chemotherapeutic Agents¹

Biophysics Department, Institute of Cancer Research, Sutton, Surrey SM2 5PX, England

Survival curves are presented for the treatment of B16 melanomas with a range of single doses of cyclophosphamide (CY), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), or 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU). When these four drugs are assessed in terms of the tumor cell kill at the lethal dose to 10% of the mice, MeCCNU is found to be much the most effective, followed by CCNU, and then CY and BCNU together. The superiority of MeCCNU is possibly related to the fact that it seems to be longer lived in the mice than are the other drugs. Combined drug and irradiation experiments have indicated that CY kills both oxygenated and hypoxic cells in the tumor, leaving proportions equal to those in the tumor prior to treatment, whereas BCNU preferentially spares the hypoxic cells. Since hypoxic cells constitute a population of cells that is at a distance from blood vessels, this result suggests that CY treatment of B16 melanomas is not limited by an inability of the drug to diffuse to cells away from blood vessels.

¹ This work was partly supported by National Cancer Institute Contract NO1-CM23717.

² To whom reprint requests should be addressed, at Physics Division, Ontario Cancer Institute, 500 Sherbourne Street, Toronto, Ontario M4X 1K9, Canada.

Received 9/23/74. Accepted 1/21/75.